GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Cyclically Adjusted Revenue per Share

US Stem Cell (US Stem Cell) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

US Stem Cell's adjusted revenue per share for the three months ended in Dec. 2022 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-09), US Stem Cell's current stock price is $0.0001. US Stem Cell's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2022 was $0.00. US Stem Cell's Cyclically Adjusted PS Ratio of today is .


US Stem Cell Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for US Stem Cell's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Cyclically Adjusted Revenue per Share Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.72 1.17 - - -

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of US Stem Cell's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, US Stem Cell's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Stem Cell's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Cyclically Adjusted PS Ratio falls into.



US Stem Cell Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, US Stem Cell's adjusted Revenue per Share data for the three months ended in Dec. 2022 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=0/125.2218*125.2218
=0.000

Current CPI (Dec. 2022) = 125.2218.

US Stem Cell Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201303 0.022 98.209 0.028
201306 0.092 98.518 0.117
201309 0.130 98.790 0.165
201312 0.113 98.326 0.144
201403 0.786 99.695 0.987
201406 1.227 100.560 1.528
201409 1.118 100.428 1.394
201412 0.877 99.070 1.109
201503 0.781 99.621 0.982
201506 0.604 100.684 0.751
201509 0.668 100.392 0.833
201512 0.335 99.792 0.420
201603 0.346 100.470 0.431
201606 0.125 101.688 0.154
201609 0.040 101.861 0.049
201612 0.008 101.863 0.010
201703 0.005 102.862 0.006
201706 0.004 103.349 0.005
201709 0.004 104.136 0.005
201712 0.004 104.011 0.005
201803 0.005 105.290 0.006
201806 0.005 106.317 0.006
201809 0.004 106.507 0.005
201812 0.004 105.998 0.005
201903 0.003 107.251 0.004
201906 0.003 108.070 0.003
201909 0.000 108.329 0.000
201912 0.001 108.420 0.001
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


US Stem Cell  (OTCPK:USRM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


US Stem Cell Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines

From GuruFocus

USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

By PRNewswire PRNewswire 11-08-2018

Court Reports Favorable Judgment in California Stem Cell Case

By ACCESSWIRE ACCESSWIRE 09-01-2022

USRM Hires Senior VP of US & International Sales

By PRNewswire PRNewswire 09-11-2018

USRM Oral Argument in Appeal from FDA Enforcement Action

By ACCESSWIRE ACCESSWIRE 01-19-2021

Northstar Biotech and USRM BOD Members Reinvest in the Company

By ACCESSWIRE ACCESSWIRE 02-23-2021

USRM Posts Profitable Results for Second Quarter 2018

By PRNewswire PRNewswire 08-15-2018

Dr. Kristin Comella Featured on Robert Scott Bell Show

By PRNewswire PRNewswire 11-09-2018